For a long time, Legal Alliance had been protecting the interests of a pharmaceutical company in a dispute regarding the obligation of the Ministry of Economic Development and Trade and Agriculture of Ukraine to amend the claim, since the indicated amount of one of the excipients was 1.0 mass % instead of 0.73 mass %. When representing client`s interests Legal Alliance lawyers underlined the rejection being unreasonable as well as on the fact that the error was technical and obvious, and did not extend patent protective right.
To prove the mentioned facts, the lawyers used British judges` approach according to which any numerical values shall be interpreted based on the general context in which they are used. For instance, “1" may be viewed as “one” (no more, no less), but at the same time, respective technology area experts may look at “one” as a range of values that go beyond an integral number.
In addition, court expert`s research proved that the patentee did not intend to limit lower threshold of the substance quantitative content in the claim by 1.0 mass %.
Therefore, having applied unconventional approach to prove and generate expert research question, Legal Alliance won this court case.
Client`s interests were defended by company`s Advisor Vitalii Savchuk, as well as lawyer and attorney Nataliia Abramovych.
The event focused on the transformation of Ukraine's intellectual property sector on its path toward European integration.
Improving access to safe and affordable medicines for the Ukrainian population is one of the Government of Ukraine's top priorities. SAFEMed Activity (2017-2025) has supported this effort by appIying health system strengthening best practices.
The Ministry of Health website has posted a notice about the release of a revised draft order of the Ministry of Health ‘On Approval of Amendments to Certain Re
On 25 September, a webinar was held on the topic: ‘180 days of new drug price regulation. Results, prospects and practical advice.’ The event was organized by LA Law Firm in partnership with Proxima Research International.